Effect of N-methyl D-aspartate (NMDA) Receptor Antagonist Dextromethorphan on Opiods Analgesia and Tolerance in Pediatric Intensive Care Unit Patients

Effect of N-methyl D-aspartate (NMDA) Receptor Antagonist Dextromethorphan on Opiods Analgesia and Tolerance in Pediatric Intensive Care Unit Patients

Effect of N-methyl D-aspartate (NMDA) receptor antagonist Dextromethorphan on Opiods analgesia and tolerance in Pediatric Intensive Care Unit Patients

Inclusion:

• Patients above 2 years, admitted in PICU
• On Morphine or Fentanyl infusions for more than 48 hours

Exclusion Criteria:

• Patients under 2 years of age
• Patients with anticipated PICU length of stay less than 3 days.
• Patients shall be excluded if Morphine or Fentanyl infusions not continued for the minimum duration of 72 hours after enrollment
• Patients develops hemodynamic instability
• Patients with Hepatic failure
• Withdrawal request by parent(s)/guardian/family